Compare BridgeBio Pharma Inc (BBIO) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs NIO Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while NIO Inc. trades at $4.56 (market cap $12.12B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| BBIO | NIO | |
|---|---|---|
Market Cap | $16.61B | $12.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $7.89 |
52-Week Low | $47.29 | $4.44 |
Enterprise Value | $18.16B | $11.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
NIO trades at $4.74, up 3.04% today but remains under pressure with a bearish technical signal. The company shows strong revenue growth to $87.49 billion in 2025, but profitability remains elusive with a net loss of $15.57 billion. Analyst sentiment is mixed with a 54% buy rating, while recent news highlights delivery growth amid a challenging EV market.
NIO's outlook hinges on achieving profitability amid fierce competition. The stock offers potential for recovery if cost controls improve and deliveries accelerate, but risks include persistent losses, high debt, and macroeconomic pressures in China. Investor patience is required given the long path to sustained earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
